Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment

Diabetes Care

Volumn 31, Issue 2, 2008, Pages 328-334

  Glintborg, Dorte ^a,c   Højlund, Kurt ^a   Andersen, Marianne ^a   Henriksen, Jan Erik ^a   Beck Nielsen, Henning ^a   Handberg, Aase ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD36 ANTIGEN; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; PIOGLITAZONE;

ANKLE EDEMA; ANXIETY; ARTICLE; ATHEROSCLEROSIS; BODY COMPOSITION; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT;

ANTIGENS, CD; ANTIGENS, CD26; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; C-REACTIVE PROTEIN; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; LIPOPROTEINS, LDL; PLACEBOS; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; THIAZOLIDINEDIONES;

EID: 38949088666     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-1424     Document Type: Article

References (23)

1. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen P, Schousboe K, Hermann AP: The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian, premenopausal women with hirsutism as primary diagnosis. Fertil Steril 82:1570-1579, 2004
2. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71:599-604, 1992
3. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A: The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89:3696-3701, 2004
4. Orio F, Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 90:2-5, 2005
5. Nasiek M, Kos-Kudla B, Ostrowska Z, Marek B, Kudla M, Sieminska L, Kajdaniuk D, Foltyn W, Zemczak A: Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 14:23-28, 2007
6. Febbraio M, Hajjar DP, Silverstein RL: CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 108:785-791, 2001
7. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-1056, 2000
8. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR: Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 113:764-773, 2004
9. Handberg A, Levin K, Hojlund K, Beck-Nielsen H: Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 114:1169-1176, 2006
10. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC: Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo-controlled study. Fertil Steril 87:202-206, 2007
11. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B: Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 153:115-121, 2005
12. Glintborg D, Stoving RK, Hagen C, Hermann AP, Frystyk J, Veldhuis JD, Flyvbjerg A, Andersen M: Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab 90:5605-5612, 2005
13. Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE: Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 86:385-397, 2006
14. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, Micic S, Moller S, Svenstrup B: Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf) 23:385-393, 1985
15. Altman DG: Comparing groups, continuous data. In Practical Statistics for Medical Research. London, Chapman & Hall/CRC, 1991, p. 199-202
16. Rosendorff C: Effects of LDL cholesterol on vascular function. J Hum Hypertens 16 (Suppl. 1):S26-S28, 2002
17. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N: Oxidised low-density lipoprotein concentration: early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155:131-136, 2006
18. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19-25, 2004
19. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N: Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 54:447-453, 2001
20. Yeh ET, Anderson HV, Pasceri V, Willerson JT: C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104:974-975, 2001
21. Puder JJ, Varga S, Kraenzlin M, De GC, Keller U, Muller B: Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 90:6014-6021, 2005
22. Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C: The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150:525-532, 2004
23. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millan JL: Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46:625-633, 2003